Drug Trial Radar · NCT07721259
A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Dec 15, 2026
Primary completion
Jul 16, 2029
Study completion Jul 16, 2030
Sponsor
- Lead sponsor
- University of WashingtonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- United States Department of Defense
- First posted
- Jul 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial evaluates whether a multi-antigen vaccine called STEMVAC improves disease-free survival after surgery in patients with triple-negative breast cancer (TNBC) and moderate or extensive residual cancer burden. TNBC has an aggressive clinical course and poorer disease-free survival compared to other subtypes. While patients who have no remaining tumor in the breast or lymph nodes after surgery have excellent long-term outcomes, patients with moderate or extensive residual cancer burden remain at high risk for early disease return and poorer prognosis. STEMVAC is designed to target proteins that tumor cells use when they become more aggressive and start to spread, and it is believed to work by boosting the immune system to recognize and destroy the invader tumor cells that are causing the disease. Giving STEMVAC after surgery may improve disease-free survival rates in TNBC patients with moderate or extensive residual cancer burden.
Conditions
- Anatomic Stage I Breast Cancer AJCC v8
- Anatomic Stage II Breast Cancer AJCC v8
- Anatomic Stage III Breast Cancer AJCC v8
- Triple-Negative Breast Carcinoma
Interventions
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA VaccineBiological
Given ID
Recombinant Granulocyte-Macrophage Colony-Stimulating FactorDrug
Given ID
Biospecimen CollectionProcedure
Undergo collection of blood samples
Primary outcomes
What the sponsor says the trial is designed to measure.
- Invasive breast cancer free survival (IBCFS)Time frame: Time from randomization to local or distant recurrence or death, assessed up to 3 years
- Dynamics and characteristics of circulating tumor deoxyribonucleic acid (ctDNA)Time frame: Up to 3 weeks after last vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.